POLE and endometrial carcinoma: This subtype is characterized by high mutational rates (above 100 mutations per megabase) attributed to POLE mutations, and it has a high rate of 5-year recurrence-free survival rate for patients with grade 3 early endometrial carcinomas, above 96% [26].